Rifaximin - Alfa Wassermann

Drug Profile

Rifaximin - Alfa Wassermann

Alternative Names: Dermodis; EIR formulation of rifaximin - Salix Pharmaceuticals; Flonorm; L-105; Lumenax; Normix; RedActive®; Rifacol; Rifaxidin®; Rifaximin soluble solid dispersion tablet; Rifaximin SSD/next generation formulation; Rifaximin-a 550mg; rifaximin-alpha; Rifxima; Spiraxin; Targaxan 550; Tixtar; Xifaxan; Xifaxan 550mg; XIFAXAN550; Xifaxanta; Zaxine

Latest Information Update: 11 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alfa Wassermann SpA
  • Developer Alfa Wassermann SpA; ASKA Pharmaceutical; Lupin; Norgine; Salix Pharmaceuticals
  • Class Antibacterials; Antidiarrhoeals; Irritable bowel syndrome therapies; Rifamycins; Small molecules
  • Mechanism of Action DNA-directed RNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatic encephalopathy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diverticulitis; Hepatic encephalopathy; Hyperammonaemia; Intestinal infections; Irritable bowel syndrome; Skin and soft tissue infections; Traveller's diarrhoea
  • Phase III Crohn's disease
  • Phase II Liver disorders
  • Discontinued Bacterial vaginosis; Clostridium-difficile-infections; Pouchitis; Shigella infections

Most Recent Events

  • 03 Jun 2018 Adverse events data from a phase III trial in Irritable bowel syndrome released by Salix Pharmaceuticals
  • 02 Jun 2018 Adverse events data from the phase III TARGET 3 trial in Irritable bowl syndrome presented at the Digestive Disease Week 2018 (DDW-2018)
  • 03 May 2018 Valeant Pharmaceuticals International plans a phase II trial for Hepatic Encephalopathy in May 2018 (NCT03515044)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top